Alpha Cognition Inc logo

Alpha Cognition Inc(ACOG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$8.3
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ACOG

11/13/2026: ACOG (1-star) is currently NOT-A-BUY. Pass it for now.

Alpha Cognition Inc is a micro-cap biopharmaceutical stock focused on developing and commercializing treatments for neurodegenerative disorders, anchored by its approved flagship product ZUNVEYL. The company's core strength lies in its differentiated product formulation designed to mitigate gastrointestinal side effects, supported by a targeted long-term care commercial strategy. Its primary growth story revolves around scaling commercial sales and advancing pipeline assets for traumatic brain injury. However, investors face notable risks including ongoing operational losses, intense competition from generic alternatives, and potential equity dilution. The stock suits high-risk growth investors willing to monitor commercial uptake metrics and capital execution closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-growth potential driven by the early commercialization phase of its lead Alzheimer's treatment.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on positive technical upturn signals and news-driven catalysts in its small-cap biotech shares.
Value investorWeak fitThe company currently operates at a net loss and lacks established earnings or free cash flow stability.
Dividend investorWeak fitAlpha Cognition does not pay dividends and retains all capital to fund commercialization and research.
Low-risk investorWeak fitHigh clinical, regulatory, execution, and price volatility risks make it unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap biotechnology stocks frequently experience sharp price swings based on clinical updates and market sentiment.
Valuation riskMedium / highValuation is heavily dependent on future sales projections rather than current trailing earnings.
Competition risk (Alzheimer's therapeutics)HighThe company faces intense competition from established large-cap pharmaceutical corporations and low-cost generics.
Business qualityMediumThe business model centers on promising intellectual property and an approved flagship product, but lacks long-term operational scale.
Dividend incomeLow / noneNo dividend payouts are offered to income-seeking investors.
Execution riskHighSuccess relies heavily on executing a niche commercial strategy within long-term care facilities.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 182.94M USD
Price to earnings Ratio -
1Y Target Price 18.2
Price to earnings Ratio -
1Y Target Price 18.2
Volume (30-day avg) 99.3K shares
Beta 2.33
52 Weeks Range 4.50 - 10.14
Updated Date 11/15/2026
52 Weeks Range 4.50 - 10.14
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.32

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 5.41%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ACOG receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ACOG has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-41.2%), weak cash generation (FCF margin -202.3%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ACOG's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 87.6%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ACOG's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-41.2%, negative) and free-cash-flow growth (-165.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 60.0% and approximately 50.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.13% supports management-shareholder alignment.

Top 5 Institutional Investors

Opaleye Management Inc 13.17%
Solas Capital Management LLC 8.75%
Awm Investment Company Inc 7.61%
Cable Car Capital LLC 6.29%
Ikarian Capital, LLC 3.80%

Unit Economics (Per $1K Revenue)

★★★★★
ACOG generates approximately $813 of gross profit, $-2,217 of operating income, and $-2,023 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ACOG has a High Volatility Profile profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
ZUNVEYL Commercial SalesDirect commercial sales of the ZUNVEYL oral tablet formulation for Alzheimer's disease primarily targeting long-term care facilities.Revenue depends directly on how effectively the company's specialized sales team can drive adoption among institutional healthcare providers.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 26.88
Enterprise Value 135.53M
Price to Sales(TTM) 11.99
Enterprise Value 135.53M
Price to Sales(TTM) 11.99
Enterprise Value to Revenue 8.88
Enterprise Value to EBITDA -1.57
Shares Outstanding 22.04M
Shares Floating 11.02M
Shares Outstanding 22.04M
Shares Floating 11.02M
Percent Insiders 5.13
Percent Institutions 60.03

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.